Summary As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive
care unit (ICU) community must prepare for the challenges associated with this pandemic …

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …

The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for
the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to …

Abstract As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019)
pandemic has swept through 213 countries and infected more than 1,870,000 individuals …

Summary Background Middle East respiratory syndrome (MERS) coronavirus causes a
highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or …

Abstract The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in
2012 marked the second introduction of a highly pathogenic coronavirus into the human …

Human coronaviruses cause both upper and lower respiratory tract infections in humans. In
2012, a sixth human coronavirus (hCoV) was isolated from a patient presenting with severe …

With the objective of linking early findings relating to the novel SARS-CoV-2 coronavirus
with potentially informative findings from prior research literature and to promote …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Abstract As of May 1, 2017, 74 antibody-based molecules have been approved by a
regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based …